JP2001511650A - 造血及び血管生成の調節方法 - Google Patents
造血及び血管生成の調節方法Info
- Publication number
- JP2001511650A JP2001511650A JP53504298A JP53504298A JP2001511650A JP 2001511650 A JP2001511650 A JP 2001511650A JP 53504298 A JP53504298 A JP 53504298A JP 53504298 A JP53504298 A JP 53504298A JP 2001511650 A JP2001511650 A JP 2001511650A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- compound
- hematopoiesis
- angiogenesis
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 127
- 230000011132 hemopoiesis Effects 0.000 title claims abstract description 103
- 230000033115 angiogenesis Effects 0.000 title claims description 80
- 230000001105 regulatory effect Effects 0.000 title description 21
- 230000000694 effects Effects 0.000 claims abstract description 42
- 230000035755 proliferation Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 152
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 210000001519 tissue Anatomy 0.000 claims description 107
- 150000001875 compounds Chemical class 0.000 claims description 100
- 239000008280 blood Substances 0.000 claims description 79
- 210000004369 blood Anatomy 0.000 claims description 78
- 210000001161 mammalian embryo Anatomy 0.000 claims description 77
- 210000001900 endoderm Anatomy 0.000 claims description 71
- 230000014509 gene expression Effects 0.000 claims description 71
- 230000009278 visceral effect Effects 0.000 claims description 69
- 210000002257 embryonic structure Anatomy 0.000 claims description 65
- 210000001654 germ layer Anatomy 0.000 claims description 60
- 210000003716 mesoderm Anatomy 0.000 claims description 51
- 108090000031 Hedgehog Proteins Proteins 0.000 claims description 49
- 102000003693 Hedgehog Proteins Human genes 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 210000000130 stem cell Anatomy 0.000 claims description 46
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 45
- 108091005879 Hemoglobin subunit epsilon Proteins 0.000 claims description 41
- 210000002459 blastocyst Anatomy 0.000 claims description 41
- 210000001325 yolk sac Anatomy 0.000 claims description 39
- 238000003556 assay Methods 0.000 claims description 37
- 230000009261 transgenic effect Effects 0.000 claims description 36
- 102100030826 Hemoglobin subunit epsilon Human genes 0.000 claims description 33
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 33
- 241001465754 Metazoa Species 0.000 claims description 29
- 238000011830 transgenic mouse model Methods 0.000 claims description 29
- 241000289669 Erinaceus europaeus Species 0.000 claims description 26
- 210000001172 blastoderm Anatomy 0.000 claims description 26
- 241000699660 Mus musculus Species 0.000 claims description 23
- 208000007502 anemia Diseases 0.000 claims description 21
- 210000000267 erythroid cell Anatomy 0.000 claims description 20
- 239000003550 marker Substances 0.000 claims description 19
- 210000001185 bone marrow Anatomy 0.000 claims description 18
- 230000003394 haemopoietic effect Effects 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 18
- 230000004936 stimulating effect Effects 0.000 claims description 18
- 238000010186 staining Methods 0.000 claims description 17
- 230000001605 fetal effect Effects 0.000 claims description 14
- 230000002159 abnormal effect Effects 0.000 claims description 13
- 239000000556 agonist Substances 0.000 claims description 12
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 11
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- 241000027355 Ferocactus setispinus Species 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 7
- 230000001744 histochemical effect Effects 0.000 claims description 7
- 230000035935 pregnancy Effects 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000002308 embryonic cell Anatomy 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 5
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 230000013011 mating Effects 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 3
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 3
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 3
- 210000002798 bone marrow cell Anatomy 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000000921 morphogenic effect Effects 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 2
- 102000043168 TGF-beta family Human genes 0.000 claims description 2
- 108091085018 TGF-beta family Proteins 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000005090 green fluorescent protein Substances 0.000 claims description 2
- 238000000099 in vitro assay Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 230000001960 triggered effect Effects 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 210000004976 peripheral blood cell Anatomy 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 208000020459 Anaemia of malignant disease Diseases 0.000 claims 1
- 101000896144 Enterococcus phage phiEF24C Virion protein 3 Proteins 0.000 claims 1
- 101000794335 Escherichia phage Mu Tail tube protein Proteins 0.000 claims 1
- 208000001911 Idiopathic aplastic anemia Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000004020 conductor Substances 0.000 claims 1
- 235000021185 dessert Nutrition 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000006444 vascular growth Effects 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 description 42
- 238000011161 development Methods 0.000 description 41
- 230000015572 biosynthetic process Effects 0.000 description 38
- 239000000047 product Substances 0.000 description 31
- 210000000601 blood cell Anatomy 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 21
- 230000035772 mutation Effects 0.000 description 21
- 108700019146 Transgenes Proteins 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 16
- 108060003196 globin Proteins 0.000 description 16
- 238000003757 reverse transcription PCR Methods 0.000 description 16
- 102000018146 globin Human genes 0.000 description 15
- 230000007045 gastrulation Effects 0.000 description 14
- 102000000017 Patched Receptors Human genes 0.000 description 13
- 108010069873 Patched Receptors Proteins 0.000 description 13
- 239000013615 primer Substances 0.000 description 13
- 102000007469 Actins Human genes 0.000 description 12
- 108010085238 Actins Proteins 0.000 description 12
- 230000000925 erythroid effect Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 241000051107 Paraechinus aethiopicus Species 0.000 description 11
- 210000003981 ectoderm Anatomy 0.000 description 11
- 210000002242 embryoid body Anatomy 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 11
- 238000010561 standard procedure Methods 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000010240 RT-PCR analysis Methods 0.000 description 9
- 230000003511 endothelial effect Effects 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000007901 in situ hybridization Methods 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102100039064 Interleukin-3 Human genes 0.000 description 8
- 108010002386 Interleukin-3 Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 210000003013 erythroid precursor cell Anatomy 0.000 description 8
- 230000010437 erythropoiesis Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 210000005166 vasculature Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 229940076264 interleukin-3 Drugs 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000001704 mesoblast Anatomy 0.000 description 7
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 210000002960 bfu-e Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000010091 embryonic hemopoiesis Effects 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000003924 normoblast Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 4
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 101710100588 Erythroid transcription factor Proteins 0.000 description 3
- 102100031690 Erythroid transcription factor Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 241000282376 Panthera tigris Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000001643 allantois Anatomy 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 101150067309 bmp4 gene Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 210000001811 primitive streak Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000002993 trophoblast Anatomy 0.000 description 3
- 230000004862 vasculogenesis Effects 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102000013602 Cardiac Myosins Human genes 0.000 description 2
- 108010051609 Cardiac Myosins Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001083591 Homo sapiens Hemoglobin subunit epsilon Proteins 0.000 description 2
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 2
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 2
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 2
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 101150030388 bin gene Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004952 blastocoel Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000004039 endoderm cell Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000349709 Echinosorex gymnura Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100031939 Erythropoietin Human genes 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 101710169105 Minor spike protein Proteins 0.000 description 1
- 101710081079 Minor spike protein H Proteins 0.000 description 1
- 101001066269 Mus musculus Erythroid transcription factor Proteins 0.000 description 1
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 1
- 101001046588 Mus musculus Krueppel-like factor 1 Proteins 0.000 description 1
- 101100404586 Mus musculus Nfe2 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000006481 angiogenic pathway Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 208000015322 bone marrow disease Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108010048996 interstitial retinol-binding protein Proteins 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000023061 limb morphogenesis Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- -1 more specifically Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000002996 primitive erythroblast Anatomy 0.000 description 1
- 230000003999 primitive hemopoiesis Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000000468 rubriblast Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000008410 smoothened signaling pathway Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000143 trophectoderm cell Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.未分化の中胚葉由来細胞の集団を、造血及び血管生成の少なくとも一方を経 験するように刺激する方法であって、以下の工程: (a) 胚の胚体外組織において発現される遺伝子産物と機能的に同等の化合 物を選択する工程;及び (b) 上記細胞が造血及び血管生成の少なくとも一方を経験するように、上 記細胞への上記化合物の接近を引き起こす工程 を含む方法。 2.上記化合物が、分泌タンパクである、請求項1記載の方法。 3.上記タンパクが、ヘッジホグタンパクである、請求項1記載の方法。 4.上記化合物が、ヘッジホグタンパク結合レセプターのアゴニストである、請 求項3記載の方法。 5.ヘッジホグタンパク結合レセプターが、patchedである、請求項4記 載の方法。 6.上記化合物が、Gliの強化された発現を引き起こす、請求項1記載の方法 。 7.ヘッジホグ化合物が、インディアン・ヘッジホグ、デザート・ヘッジホグ及 びソニック・ヘッジホグ化合物からなる群から選択される、請求項3記載の 方法。 8.上記化合物が、インディアン・ヘッジホグ化合物である、請求項3記載の方 法。 9.上記化合物が、第一の遺伝子産物に由来する第一の化合物であり、造血及び 血管生成の少なくとも一方の刺激を強化するように、胚体外組織において発 現される第二の遺伝子産物に由来する第二の化合物と相乗的に作用すること ができる、請求項1記載の方法。 10.上記第二の化合物が、TGF−βファミリーのメンバーの機能的同等物であ る、請求項9記載の方法。 11.上記TGF−βが、BMP−2、BMP−4、BMP−6及びBMP−7か らなる群から選択される、請求項9記載の方法。 12.胚体外組織が、内臓内胚葉である、請求項1記載の方法。 13.胚体外組織が、卵黄嚢中胚葉である、請求項1記載の方法。 14.工程(b)が上記化合物を培地中に提供することを含むように、培地中でイ ンビトロで上記細胞集団を維持する工程をさらに含む、請求項1記載の方法 。 15.細胞が、造血幹細胞の集団である、請求項14記載の方法。 16.造血幹細胞が、臍帯血細胞、胎児抹消血細胞及び胎児肝細胞からなる群から 選択される、請求項15記載の方法。 17.造血幹細胞が、成体骨髄細胞である、請求項15記載の方法。 18.細胞が、成人から得られる前駆細胞である、請求項14記載の方法。 19.細胞が、上記化合物により刺激される場合、血管生成をすることができる成 人からの前駆細胞である、請求項14記載の方法。 20.細胞が、胚組織を構成する、請求項14記載の方法。 21.細胞が、胚性外植片培養物を構成する、請求項20記載の方法。 22.胚性外植片培養物が、胚盤胞である、請求項21記載の方法。 23.細胞が、動物の骨髄内のインビボ造血幹細胞である、請求項1記載の方法。 24.細胞が、動物内に存在する造血幹細胞であり、かつ、骨髄、臍帯血細胞、胎 児抹消血細胞及び胎児肝細胞の少なくとも1つにおいて見出される造血細胞 の群から選択される、請求項1記載の方法。 25.経口、皮内、皮下、経粘膜、筋内又は静脈内経路のいずれかによって動物に 有効用量の上記化合物を投与することにより、上記化合物の幹細胞への接近 を引き起こすことをさらに含む、請求項24記載の方法。 26.上記化合物が、骨髄形態形成タンパク(BMP)ファミリーからのタンパク と機能的に同等である、請求項2記載の方法。 27.子宮内の胚における血管生成又は造血の発生エラーを処置する方法であって 、以下の工程: (a) 胚体外組織において発現される遺伝子産物と機能的に同等の化合物の 有効用量を選択する工程;及び (b) 胚細胞が造血及び血管生成の少なくとも一方を経験するように、イン ビボで胚細胞の集団への上記化合物の接近を引き起こす工程 を含む方法。 28.上記化合物が、ヘッジホグタンパクレセプターのアゴニストである、請求項 27記載の方法。 29.上記化合物が、ヘッジホグタンパクである、請求項27記載の方法。 30.上記化合物が、胚細胞における造血の刺激を強化するように、胚体外組織に おいて発現される第二の遺伝子産物に由来する第二の化合物と相乗的に作用 することができる第一の化合物である、請求項27記載の方法。 31.異常な数のエリスロイド細胞を経験している個体を処置する方法であって、 以下の工程: (a) 胚体外組織において発現される遺伝子産物と機能的に同等の化合物の 有効用量を選択する工程;及び (b) 増殖又は造血の少なくとも一方を経験している異常な数の細胞を調節 するように有効な時間にわたって造血幹細胞の集団への上記化合物の接近 を引き起こす工程 を含む方法。 32.上記化合物が、ヘッジホグタンパクレセプターのアゴニストであり、造血幹 細胞が、増殖又は造血の少なくとも一方を経験するように刺激される、請求 項31記載の方法。 33.上記化合物が、ヘッジホグタンパクである、請求項32記載の方法。 34.上記化合物が、造血幹細胞の造血の刺激を強化するように、胚体外組織にお いて発現される第二の遺伝子産物に由来する第二の化合物と相乗的に作用す ることができる第一の化合物である、請求項31記載の方法。 35.上記化合物が、ヘッジホグタンパクのアンタゴニストであり、造血幹細胞が 、増殖又は造血の一方を経験することを阻害される、請求項31記載の方法 。 36.異常な数のエリスロイド細胞が、個体における貧血を特徴とする異常に少数 のエリスロイド細胞であり、その貧血が、特発性再生不良性貧血、素質型再 生不良性貧血、再生不良性貧血の二次的な型、骨髄形成異常性貧血、ウイル スによる慢性貧血、慢性炎症性疾患による貧血、ガンによる貧血、器官障害 により誘発された慢性貧血、血小板減少症及び薬剤による貧血からなる群か ら選択される、請求項31記載の方法。 37.異常な数のエリスロイド細胞が、真性赤血球増加症及び赤白血病からなる群 から選択される疾患を引き起こす、請求項31記載の方法。 38.組織における虚血を経験する個体を処置する方法であって、以下の工程: (a) 胚体外組織において発現される遺伝子産物と機能的に同等の化合物の 有効用量を選択する工程;及び (b) 虚血組織内での血管生成を刺激するように有効な時間にわたって虚血 部位に上記化合物を投与する工程 を含む方法。 39.虚血が、心筋虚血である、請求項37記載の方法。 40.上記化合物が、ヘッジホグタンパクレセプターのアゴニストである、請求項 38記載の方法。 41.上記化合物が、ヘッジホグタンパクである、請求項40記載の方法。 42.上記化合物が、血管生成の刺激を強化するように、胚体外組織において発現 される第二の遺伝子産物に由来する第二の化合物と相乗的に作用することが できる第一の化合物である、請求項39記載の方法。 43.個体において異常に強化された血管生成を処置する方法であって、以下の工 程: (a) 胚体外組織において発現される遺伝子産物の活性を阻害することがで きるヘッジホグタンパクの有効用量を選択する工程;及び (b)異常に強化された血管生成を阻害するように有効な時間にわたって個体 に上記化合物を投与する工程 を含む方法。 44.造血又は血管生成を調節することができる化合物の活性を決定するためのイ ンビトロアッセイであって、以下の工程: (a) 哺乳類の受精卵に由来する組織からの細胞の集団であって、上記細胞 の集団は、予め決定されたマーカーの欠如により検出可能なように血液形 成において欠陥を有するものである細胞の集団を選択する工程;及び (b) 上記欠陥を逆転するように上記細胞の集団に薬剤を添加する工程 を含む方法。 45.上記細胞の集団が、胚盤胞である、請求項44記載の方法。 46.上記細胞の集団が、胚盤葉上層であり、この胚盤葉上層が、内臓内胚葉の欠 如を特徴とし、組織学的染色により検出可能なように血島の出現の前に哺乳 類から単離されたもののである、請求項44記載の方法。 47.上記細胞の集団が、胚盤葉上層の部分であり、この部分が、前部部分であり 、この胚盤葉上層が、組織学的染色により検出可能なように前部部分の血島 の出現の前に哺乳類から単離されたものである、請求項44記載の方法。 48.哺乳類が、トランスジェニックマウスである、請求項47記載の方法。 49.トランスジェニックマウスが、マウスゲノムの改変により作製されている、 請求項48記載の方法。 50.上記改変が、DNA配列のランダム挿入、DNA配列のターゲティングされ た挿入、DNA配列のターゲティングされた欠失及びDNA配列のターゲテ ィングされた置換の1つから選択される、請求項49記載の方法。 51.トランスジェニックマウスが、上記改変に関してホモ接合性である、請求項 50記載の方法。 52.造血又は血管生成を調節することができる化合物の活性を決定するためのア ッセイであって、以下の工程: (a) マーカー:ε−グロビンハイブリッド遺伝子であって、ε−グロビン 遺伝子が少なくとも15.5dpcまで発現をすることができるものを有 する第一のトランスジェニック動物を選択する工程; (b) 第一のトランスジェニック動物を、同様にトランスジェニックである 第二の動物と交配する工程; (c) 妊娠期間中にこの交配からの胚を単離する工程;及び (d) マーカー発現を測定することによって単離された胚における造血及び 血管生成の刺激に対する化合物の影響を決定する工程 を含むアッセイ。 53.工程(d)に先行するさらなる工程が、胚体外組織から胚性組織を分離する ことを含む、請求項52記載の方法。 54.マーカーが、LacZ、アルカリホスファターゼ、緑色蛍光タンパク及び誘 導体からなる群から選択される組織化学的マーカーである、請求項52記載 のアッセイ。 55.胚が、マウス胚であり、このマウス胚が、およそ6.0〜12.0dpcの 間に単離される、請求項52記載のアッセイ。 56.胚が、マウス胚であり、このマウス胚が、およそ3.5〜3.75dpcの 間に単離される、請求項52記載のアッセイ。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3751397P | 1997-02-10 | 1997-02-10 | |
US60/037,513 | 1997-02-10 | ||
US4976397P | 1997-06-16 | 1997-06-16 | |
US60/049,763 | 1997-06-16 | ||
US09/021,660 US6713065B2 (en) | 1997-02-10 | 1998-02-10 | Methods of using hedgehog proteins to modulate hematopoiesis and vascular growth |
PCT/US1998/002633 WO1998035020A2 (en) | 1997-02-10 | 1998-02-10 | Methods for modulating hematopoiesis and vascular growth |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009136272A Division JP2009261956A (ja) | 1997-02-10 | 2009-06-05 | 造血及び血管生成の調節方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001511650A true JP2001511650A (ja) | 2001-08-14 |
JP2001511650A5 JP2001511650A5 (ja) | 2005-10-06 |
JP4669968B2 JP4669968B2 (ja) | 2011-04-13 |
Family
ID=27361699
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53504298A Expired - Fee Related JP4669968B2 (ja) | 1997-02-10 | 1998-02-10 | 造血及び血管生成の調節方法 |
JP2009136272A Pending JP2009261956A (ja) | 1997-02-10 | 2009-06-05 | 造血及び血管生成の調節方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009136272A Pending JP2009261956A (ja) | 1997-02-10 | 2009-06-05 | 造血及び血管生成の調節方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US6713065B2 (ja) |
EP (1) | EP1019490B1 (ja) |
JP (2) | JP4669968B2 (ja) |
AT (1) | ATE449836T1 (ja) |
CA (1) | CA2280736C (ja) |
DE (1) | DE69841320D1 (ja) |
DK (1) | DK1019490T3 (ja) |
ES (1) | ES2339724T3 (ja) |
WO (1) | WO1998035020A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005097170A1 (ja) * | 2004-03-30 | 2005-10-20 | Niigata Tlo Corporation | 血管新生促進剤および血管新生療法 |
JP2009261956A (ja) * | 1997-02-10 | 2009-11-12 | President & Fellows Of Harvard College | 造血及び血管生成の調節方法 |
JP2012508764A (ja) * | 2008-11-13 | 2012-04-12 | ザ・ジェネラル・ホスピタル・コーポレイション | Bmp−6の調節によって鉄の恒常性を制御するための方法および組成物 |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8173098A (en) | 1997-06-27 | 1999-01-19 | Ontogeny, Inc. | Neuroprotective methods and reagents |
US7144997B2 (en) | 1997-07-24 | 2006-12-05 | Curis, Inc. | Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto |
US6639051B2 (en) | 1997-10-20 | 2003-10-28 | Curis, Inc. | Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
US20030129750A1 (en) * | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
US7291626B1 (en) | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
WO2000015246A2 (en) | 1998-09-11 | 2000-03-23 | President And Fellows Of Harvard College | Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
US6884770B1 (en) | 1998-11-06 | 2005-04-26 | Curis, Inc. | Methods and compositions for treating or preventing peripheral neuropathies |
GB9910664D0 (en) * | 1999-05-07 | 1999-07-07 | Zeneca Ltd | Cells and assay |
ATE328002T1 (de) | 1999-10-13 | 2006-06-15 | Univ Johns Hopkins Med | Verbindungen zur regulierung des hedgehog- signalwegs, zusammensetzungen und verwendungen davon |
WO2001041786A1 (en) * | 1999-12-10 | 2001-06-14 | The General Hospital Corporation | METHODS TO STIMULATE INSULIN PRODUCTION BY PANCREATIC β-CELLS |
WO2001063281A1 (en) * | 2000-02-23 | 2001-08-30 | Musc Foundation For Research Development | Methods of screening for compounds that modulate blood vessel formation |
CA2412215A1 (en) * | 2000-06-16 | 2001-12-27 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
EP1387674B1 (en) * | 2000-10-13 | 2017-01-18 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
EP1411938B1 (en) | 2001-07-02 | 2005-07-06 | Tas, Sinan | Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
US7828101B2 (en) * | 2002-12-03 | 2010-11-09 | Radtke Jeffrey L | Self-propelled wheel for bicycles and similar vehicles |
JP4750697B2 (ja) * | 2003-06-25 | 2011-08-17 | オタワ ヘルス リサーチ インスティテュート | 幹細胞の成長及び分化を調節する方法及び組成物 |
WO2005097207A2 (en) | 2004-03-26 | 2005-10-20 | Curis, Inc. | Rna interference modulators of hedgehog signaling and uses thereof |
WO2005113749A2 (en) | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Stem cell populations and methods of use |
US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
WO2008137115A1 (en) | 2007-05-03 | 2008-11-13 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US8574567B2 (en) * | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
GB201204201D0 (en) * | 2012-03-09 | 2012-04-25 | Ucl Business Plc | Erythropoiesis |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4811522A (en) * | 1987-03-23 | 1989-03-14 | Gill Jr Gerald L | Counterbalanced polishing apparatus |
US6610656B1 (en) * | 1993-12-30 | 2003-08-26 | President And Fellows Of Harvard College | Method of promoting chondrocyte differentiation with hedgehog related polypeptides |
US5789543A (en) * | 1993-12-30 | 1998-08-04 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins and uses related thereto |
US6261786B1 (en) * | 1993-12-30 | 2001-07-17 | Imperial Cancer Res. Technology | Screening assays for hedgehog agonists and antagonists |
WO1995018856A1 (en) | 1993-12-30 | 1995-07-13 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
US6384192B1 (en) * | 1993-12-30 | 2002-05-07 | President & Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins |
US7060450B1 (en) * | 1993-12-30 | 2006-06-13 | President And Fellows Of Harvard College | Screening assays for agonists and antagonists of the hedgehog signaling pathway |
US6165747A (en) * | 1993-12-30 | 2000-12-26 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
US6884775B1 (en) * | 1993-12-30 | 2005-04-26 | President And Fellows Of Harvard College | Methods and compositions for regulating skeletogenic formation |
US20030186357A1 (en) * | 1993-12-30 | 2003-10-02 | Philip W. Ingham | Vertebrate embryonic pattern-inducing proteins, and uses related thereto |
US6566092B1 (en) * | 1994-02-25 | 2003-05-20 | The Trustees Of Columbia University In The City Of New York | DNA encoding a vertebrate homolog of hedgehog, Vhh-1, expressed by the notochord, and uses thereof |
US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
US6027882A (en) * | 1994-10-07 | 2000-02-22 | The Regents Of The University Of California | Patched genes and their use for diagnostics |
US5837538A (en) * | 1994-10-07 | 1998-11-17 | Trustees Of Leland Stanford, Jr. University | Patched genes and their use |
US6429354B1 (en) * | 1994-10-07 | 2002-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Patched genes and uses related thereto |
US6946257B1 (en) * | 1994-10-07 | 2005-09-20 | Regents Of The University Of California | Patched genes and uses related thereto |
US6281332B1 (en) | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
US5759811A (en) | 1996-11-13 | 1998-06-02 | The Regents Of The University Of California | Mutant human hedgehog gene |
DK1019490T3 (da) | 1997-02-10 | 2010-03-15 | Harvard College | Fremgangsmåder til modulering af hæmatopoese og vaskulær vækst |
US6867216B1 (en) * | 1998-04-09 | 2005-03-15 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signal pathways, compositions and uses related thereto |
US6432970B2 (en) * | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
EP1112087B1 (en) * | 1998-09-11 | 2010-02-24 | Curis, Inc. | Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor |
WO2000015246A2 (en) | 1998-09-11 | 2000-03-23 | President And Fellows Of Harvard College | Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
WO2000025725A2 (en) | 1998-11-02 | 2000-05-11 | Biogen, Inc. | Functional antagonists of hedgehog activity |
US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
GB0013674D0 (en) | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
US20050080138A1 (en) * | 1999-09-16 | 2005-04-14 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
DE60017157T2 (de) * | 1999-09-16 | 2005-12-22 | Curis, Inc., Cambridge | Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen |
US6552016B1 (en) * | 1999-10-14 | 2003-04-22 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
JP4898044B2 (ja) | 1999-10-14 | 2012-03-14 | キュリス,インコーポレイテッド | ヘッジホッグシグナル伝達経路のメディエーター、それらと関連する組成物及び利用 |
DE20022471U1 (de) * | 2000-01-08 | 2001-12-06 | Sensopart Industriesensorik Gm | Nachrüstgerät für ein Zielfernrohr |
US6613798B1 (en) * | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
ES2250377T5 (es) | 2000-03-30 | 2010-04-06 | Curis, Inc. | Moleculas organicas pequeñas reguladoras de la proliferacion celular. |
US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
CA2412215A1 (en) * | 2000-06-16 | 2001-12-27 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
JP2002100593A (ja) * | 2000-09-21 | 2002-04-05 | Nikon Corp | 研磨装置、これを用いた半導体デバイスの製造方法及びこの製造方法により製造された半導体デバイス |
EP1387674B1 (en) * | 2000-10-13 | 2017-01-18 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
JP2004534743A (ja) | 2001-04-09 | 2004-11-18 | ロランティス リミテッド | ヘッジホッグ |
NZ530580A (en) | 2001-07-27 | 2007-02-23 | Curis Inc | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
-
1998
- 1998-02-10 DK DK98906314.4T patent/DK1019490T3/da active
- 1998-02-10 WO PCT/US1998/002633 patent/WO1998035020A2/en active Application Filing
- 1998-02-10 JP JP53504298A patent/JP4669968B2/ja not_active Expired - Fee Related
- 1998-02-10 ES ES98906314T patent/ES2339724T3/es not_active Expired - Lifetime
- 1998-02-10 DE DE69841320T patent/DE69841320D1/de not_active Expired - Lifetime
- 1998-02-10 US US09/021,660 patent/US6713065B2/en not_active Expired - Lifetime
- 1998-02-10 AT AT98906314T patent/ATE449836T1/de not_active IP Right Cessation
- 1998-02-10 CA CA2280736A patent/CA2280736C/en not_active Expired - Fee Related
- 1998-02-10 EP EP98906314A patent/EP1019490B1/en not_active Expired - Lifetime
-
2004
- 2004-02-03 US US10/772,090 patent/US20050002933A1/en not_active Abandoned
-
2009
- 2009-06-05 JP JP2009136272A patent/JP2009261956A/ja active Pending
-
2012
- 2012-06-27 US US13/534,833 patent/US8691230B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
JPN6008022122, Trends in Genetics, vol.13(1), pp.14−21 (Jan.1997) * |
JPN6008022123, 細胞,vol.27, pp.337−340 (1995) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009261956A (ja) * | 1997-02-10 | 2009-11-12 | President & Fellows Of Harvard College | 造血及び血管生成の調節方法 |
WO2005097170A1 (ja) * | 2004-03-30 | 2005-10-20 | Niigata Tlo Corporation | 血管新生促進剤および血管新生療法 |
JP2012508764A (ja) * | 2008-11-13 | 2012-04-12 | ザ・ジェネラル・ホスピタル・コーポレイション | Bmp−6の調節によって鉄の恒常性を制御するための方法および組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO1998035020A3 (en) | 1999-01-14 |
EP1019490B1 (en) | 2009-11-25 |
CA2280736C (en) | 2012-05-29 |
ES2339724T3 (es) | 2010-05-24 |
EP1019490A2 (en) | 2000-07-19 |
US6713065B2 (en) | 2004-03-30 |
US20050002933A1 (en) | 2005-01-06 |
US20130071407A1 (en) | 2013-03-21 |
US8691230B2 (en) | 2014-04-08 |
CA2280736A1 (en) | 1998-08-13 |
JP4669968B2 (ja) | 2011-04-13 |
DE69841320D1 (de) | 2010-01-07 |
JP2009261956A (ja) | 2009-11-12 |
US20010041668A1 (en) | 2001-11-15 |
DK1019490T3 (da) | 2010-03-15 |
ATE449836T1 (de) | 2009-12-15 |
WO1998035020A2 (en) | 1998-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4669968B2 (ja) | 造血及び血管生成の調節方法 | |
Johnson et al. | Pleiotropic effects of a null mutation in the c-fos proto-oncogene | |
Vassalli et al. | Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. | |
US6251671B1 (en) | Compositions and methods of making embryonic stem cells | |
Bezerra et al. | Biological effects of targeted inactivation of hepatocyte growth factor-like protein in mice. | |
Kulkarni et al. | Function of cytokines within the TGF-β superfamily as determined from transgenic and gene knockout studies in mice | |
US20010013134A1 (en) | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells | |
KR101057116B1 (ko) | 포유류에서의 분화 조절제 및 분화 조절 방법 | |
EP3644720B1 (en) | Non-human model for neurofibromatosis type 1 | |
JP5080988B2 (ja) | 線維性疾患のためのモデルとしての遺伝子導入動物 | |
US20030023995A1 (en) | Inhibitor of differentiation knockout mammals and methods of use thereof | |
Fundele et al. | Proliferation and differentiation of androgenetic cells in fetal mouse chimeras | |
WO1997038091A1 (en) | METHODS FOR ENHANCING ANIMAL GROWTH AND CELL PROLIFERATION BY ELIMINATION OF FUNCTIONAL p27?Kip1¿ | |
US20030027777A1 (en) | Methods for enhancing animal growth and cell proliferation by elimination of the cyclin-dependent kinase inhibitor function of p27Kip1 | |
Wessling | Gene deletion and functional analysis of fetuin-B | |
WO2005116070A9 (en) | Reporter system for detecting signal pathway activation in multiple cell types | |
Vassalli | A genetic test of the role of activins in mouse mesoderm formation | |
US20050101536A1 (en) | Modulation of angiogenesis | |
Proetzel | Functional analysis of transforming growth factor-beta-3 using gene targeting | |
Snook | Shih" VJ Shh | |
Song | FGF8, isoform b, is an etiological factor in prostate tumorigenesis | |
Rusholme | Strain-dependent variation in developmental TGFβ1 knockout phenotypes | |
Lee | Functional analysis of EGFR using a conditional allele | |
Oakes | Investigation of the role of prolactin in mammary gland development and carcinogenesis. | |
Metzger | The Role of the ETS Transcription Factor Elf5 in Lung Development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050208 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080513 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080922 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080912 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081014 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081121 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100517 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100610 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101102 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101124 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101219 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |